Murphy Amanda Louise 4

Accession 0001209191-21-064884

CIK 0001287098other

View on SEC.gov Company Profile

Filed

Nov 15, 7:00 PM ET

Accepted

Nov 16, 7:12 PM ET

Size

21.2 KB

Accession

0001209191-21-064884

Insider Transaction Report

Form 4

Period: 2021-11-12

MAXCYTE, INC.MXCT

Murphy Amanda Louise

Chief Financial Officer

Transactions

Exercise/Conversion
Common Stock
2021-11-12$4.42/sh+51,103$225,875→ 51,103 total
Sale
Common Stock
2021-11-12$12.66/sh−51,103$646,964→ 0 total
Sale
Common Stock
2021-11-15$12.16/sh−61,591$748,947→ 0 total
Exercise/Conversion
Common Stock
2021-11-16$4.42/sh+37,306$164,893→ 37,306 total
Sale
Common Stock
2021-11-16$12.08/sh−37,306$450,656→ 0 total
Exercise/Conversion
Employee Stock Option (right to buy)
2021-11-12−51,103→ 1,098,897 total
Exercise: $4.42Exp: 2030-09-08→ Common Stock (51,103 underlying)
Exercise/Conversion
Employee Stock Option (right to buy)
2021-11-15−61,591→ 1,037,306 total
Exercise: $4.42Exp: 2030-09-08→ Common Stock (61,591 underlying)
Exercise/Conversion
Common Stock
2021-11-15$4.42/sh+61,591$272,232→ 61,591 total
Exercise/Conversion
Employee Stock Option (right to buy)
2021-11-16−37,306→ 1,000,000 total
Exercise: $4.42Exp: 2030-09-08→ Common Stock (37,306 underlying)

Footnotes (5)

[F1]This exercise price is in U.S. Dollars and reflects the conversion of GBP to USD at an exchange rate of GBP 1.00 to $1.34.
[F2]The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.56 to $12.765, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
[F3]The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.03 to $12.615, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
[F4]The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.20, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
[F5]One-sixteenth (1/16th) of the shares underlying this option vested on December 7, 2020, and the remainder vested or shall vest monthly in forty-five (45) equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

MAXCYTE, INC.

CIK 0001287098

→

Entity typeother

Related Parties

filerCIK 0001875169

Filing Metadata

Form type: 4
Filed: Nov 15, 7:00 PM ET
Accepted: Nov 16, 7:12 PM ET
Size: 21.2 KB

View on SEC.gov